DBB (Digital Bio-Banking)
A data assetization platform serving as the foundation for precision medicine
Oncocross is expanding its precision medicine data business by leveraging clinical and genomic data assets accumulated through oncoMASTER, together with its proprietary AI analytics capabilities.
We are building a data-driven value chain that spans multi-omics data generation, data assetization, diagnostics, and clinical application.
VALUE PROPOSITION
Application Value
-
Value Proposition 01
Biomarker Discovery
Discovery of novel targets and biomarkers based on multi-omics data
-
Value Proposition 02
Drug Development Support
Support for patient stratification and responder analysis
-
Value Proposition 03
Clinical Research Acceleration
Support for identifying patient cohorts under specific conditions
-
Value Proposition 04
Mechanistic Insight
Proteomics-based interpretation of disease mechanisms and functional insights
-
Value Proposition 05
Real-World Evidence
Support for research and decision-making based on real-world clinical data
Status of DBB
DBB Overview
10,000+
Clinical & Genomic Records
2,700+
Biospecimen Samples
4-Layer
Multi-Omics Data
50+
Clinical & Research Network
PARTNERING POINTS
Partnering Points
-
Point 01
Integrated Dataset
Integrated data structure linking clinical, omics, and pathology data
-
Point 02
Query-Ready Data
Data structure enabling condition-based patient cohort exploration
-
Point 03
Asia-Focused Data Advantage
Differentiated analytics foundation based on East Asian patient data
-
Point 04
Flexible Collaboration
Flexible collaboration in data analytics, joint research, and customized projects
EXAMPLE USE CASES
Application Examples
*The following cases are expected application scenarios and are not actual cases.
-
01
In patient groups with specific genetic mutations,
analysis of proteomics changes according to treatment response
-
02
Through comparison before and after immunotherapy,
identification of responder vs. non-responder characteristics
-
03
In cohorts of specific cancer types,
biomarker-based patient stratification
-
04
For discovery of new targets,
multi-omics-based pathway analysis
-
05
Based on conditions requested by pharmaceutical companies,
patient cohort exploration and data package provision
Together with Oncocross, we create new opportunities in drug discovery, diagnostics,
and data-driven expansion.
Let's Build the Next Possibility in Precision Medicine